Trial
SPRINT MIND
Research Observatory
Evidence Update
Current evidence
SPRINT MIND compared systolic blood pressure targets below 120 versus below 140 mm Hg in 9,361 adults with hypertension and elevated cardiovascular risk, assessing probable dementia and mild cognitive impairment (MCI). SPRINT MIND did not demonstrate a statistically significant primary dementia reduction, while secondary MCI findings favored intensive blood-pressure control. Longer SPRINT follow-up preserves the distinction between uncertain dementia reduction and a favorable cognitive composite; the figure-label correction does not create a new result.
What changed
SPRINT MIND and its later follow-up share a cohort; corrected Figure 3's right axis describes MCI or dementia, not dementia alone.
What did not change
Longer follow-up is not a fresh independent experiment or proof of dementia prevention.
Why it matters
Prevents a secondary composite from replacing the primary clinical question.
Main limitation
Early trial stopping reduced dementia power; intensive BP also had hypotension, syncope, electrolyte and acute kidney injury tradeoffs. The formal baseline-reporting correction corrects baseline Framingham-risk reporting, not these outcome estimates. Attrition and post-intervention follow-up; not independent replication. The figure-label correction corrects Figure 3 right y-axis to cumulative MCI or probable dementia; do not label it dementia alone.
Next proof
Longer follow-up with complete cognitive ascertainment, prespecified dementia endpoints and concurrent safety assessment.
Summary
SPRINT MIND compared systolic blood pressure targets below 120 versus below 140 mm Hg in 9,361 adults with hypertension and elevated cardiovascular risk, assessing probable dementia and mild cognitive impairment (MCI). SPRINT MIND did not demonstrate a statistically significant primary dementia reduction, while secondary MCI findings favored intensive blood-pressure control. Longer SPRINT follow-up preserves the distinction between uncertain dementia reduction and a favorable cognitive composite; the figure-label correction does not create a new result.
Intelligence Take
Prevents a secondary composite from replacing the primary clinical question.
Limitations
Early trial stopping reduced dementia power; intensive BP also had hypotension, syncope, electrolyte and acute kidney injury tradeoffs. The formal baseline-reporting correction corrects baseline Framingham-risk reporting, not these outcome estimates. Attrition and post-intervention follow-up; not independent replication. The figure-label correction corrects Figure 3 right y-axis to cumulative MCI or probable dementia; do not label it dementia alone.